This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://linked.opendata.cz/resource/drugbank/drug/DB01384/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01384/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01384/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01384/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01384/identifier/pubchem-substance/
n8http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB01384/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01384/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01384
rdf:type
n3:Drug
n3:description
A glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p737)
n3:group
approved
n3:indication
For the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone.
owl:sameAs
n8:DB01384 n9:DB01384
dcterms:title
Paramethasone
adms:identifier
n11:46504651 n12:C07413 n13:PA164777035 n14:5875 n15:5664 n16:Paramethasone n18:DB01384
n3:mechanismOfAction
Glucocorticoids such as paramethasone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Paramethasone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.
n3:routeOfElimination
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
n3:synonym
Dillar
n3:toxicity
Side effects include inhibition of bone formation, suppression of calcium absorption delayed wound healing, immune suppression, and hyperglycemia.
n3:proteinBinding
80%
n3:IUPAC-Name
n4:271B4447-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B444D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B444C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4449-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B444A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B444B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4445-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4443-363D-11E5-9242-09173F13E4C5 n4:271B4446-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4444-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:H02AB05
n3:H-Bond-Acceptor-Count
n4:271B4453-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4454-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B444E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B444F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4451-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4450-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4452-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
53-33-8
n3:Bioavailability
n4:271B4459-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B445B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B445C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4458-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4457-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B445A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4448-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4455-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4456-363D-11E5-9242-09173F13E4C5